{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:10:50Z","timestamp":1793517050280,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.mehy.2020.109920","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T11:49:00Z","timestamp":1591012140000},"page":"109920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Diacerein: A potential multi-target therapeutic drug for COVID-19"],"prefix":"10.1016","volume":"144","author":[{"given":"Pedro Gon\u00e7alves","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Termini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison Luiz","family":"Durigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Lepique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei C","family":"Sposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Boccardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.109920_b0005","first-page":"1","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"3","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.mehy.2020.109920_b0010","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"issue":"10229","key":"10.1016\/j.mehy.2020.109920_b0015","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pcl.2012.03.002","article-title":"Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes","volume":"59","author":"Canna","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.mehy.2020.109920_b0025","series-title":"The Microbiome in Rheumatic Diseases and Infection","first-page":"151","article-title":"Macrophage activation syndrome","author":"Eloseily","year":"2018"},{"issue":"6","key":"10.1016\/j.mehy.2020.109920_b0030","article-title":"Haemophagocytic lymphohistiocytosis in COVID-19 cases?","volume":"140","author":"Tveiten","year":"2020","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"10230","key":"10.1016\/j.mehy.2020.109920_b0035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40266-016-0347-4","article-title":"Diacerein: benefits, risks and place in the management of osteoarthritis. an opinion-based report from the ESCEO","volume":"33","author":"Pavelka","year":"2016","journal-title":"Drugs Aging"},{"issue":"17","key":"10.1016\/j.mehy.2020.109920_b0045","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/archinte.166.17.1899","article-title":"A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis","volume":"166","author":"Rintelen","year":"2006","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0050","article-title":"Diacerein for osteoarthritis","volume":"10","author":"Fidelix","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joca.2009.10.006","article-title":"Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Bartels","year":"2010","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1759720X09359104","article-title":"Effects of diacerein at the molecular level in the osteoarthritis disease process","volume":"2","author":"Martel-Pelletier","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40264-015-0266-z","article-title":"Benefit\u2013risk assessment of diacerein in the treatment of osteoarthritis","volume":"38","author":"Panova","year":"2015","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0070","doi-asserted-by":"crossref","first-page":"E674","DOI":"10.3390\/ijms19030674","article-title":"Therapeutics in osteoarthritis based on an understanding of its molecular pathogenesis","volume":"19","author":"Kim","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.mehy.2020.109920_b0075","first-page":"753","article-title":"In vitro effects of Diacerein and Rhein on IL-1 and TNF-\u03b1 systems in human osteoarthritic synovium and chondrocytes","volume":"25","author":"Martel-Pelletier","year":"1998","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/joca.1997.0088","article-title":"Effects of diacerhein on granuloma induced cartilage breakdown in the mouse","volume":"6","author":"Moore","year":"1998","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0085","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/joca.1998.0201","article-title":"Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures","volume":"7","author":"Yaron","year":"1999","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-0773.2002.910104.x","article-title":"Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha","volume":"91","author":"Mendes","year":"2002","journal-title":"Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/joca.1999.0289","article-title":"Diacerhein and rhein reduce the ICE-induced IL-1\u03b2 and IL-18 activation in human osteoarthritic cartilage","volume":"8","author":"Moldovan","year":"2000","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.mehy.2020.109920_b0100","first-page":"1","article-title":"Rhein: a review of pharmacological activities","volume":"2015","author":"Zhou","year":"2015","journal-title":"Evid Based Complement Altern Med"},{"issue":"4","key":"10.1016\/j.mehy.2020.109920_b0105","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902018000417534","article-title":"Diacerein, its beneficial impact on chondrocytes and notable new clinical applications","volume":"54","author":"Kaur","year":"2018","journal-title":"Braz J Pharm Sci"},{"key":"10.1016\/j.mehy.2020.109920_b0110","first-page":"154","article-title":"Pharmacological treatment with diacerein combined with mechanical stimulation affects the expression of growth factors in human chondrocytes","volume":"11","author":"Steinecker-Frohnwieser","year":"2017","journal-title":"Biochem Biophys Rep"},{"issue":"30","key":"10.1016\/j.mehy.2020.109920_b0115","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1038\/onc.2015.466","article-title":"Diacerein-mediated inhibition of IL-6\/IL-6R signaling induces apoptotic effects on breast cancer","volume":"35","author":"Bharti","year":"2015","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.mehy.2020.109920_b0120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.joca.2014.05.008","article-title":"The disease modifying osteoarthritis drug diacerein is able to antagonize pro inflammatory state of chondrocytes under mild mechanical stimuli","volume":"22","author":"Steinecker-Frohnwieser","year":"2014","journal-title":"Osteoarthr Cartil"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0125","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00011-009-0085-8","article-title":"Diacerein decreases TNF-\u03b1 and IL-1\u03b2 levels in peritoneal fluid and prevents Baker\u2019s yeast-induced fever in young rats","volume":"59","author":"Pasin","year":"2009","journal-title":"Inflamm Res"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0130","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar1028","article-title":"Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols","volume":"6","author":"Douni","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.mehy.2020.109920_b0135","first-page":"1","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"10224","key":"10.1016\/j.mehy.2020.109920_b0140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"6485","key":"10.1016\/j.mehy.2020.109920_b0145","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.mehy.2020.109920_b0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","article-title":"Comparative genetic analysis of the novel coronavirus (2019-nCoV\/SARS-CoV-2) receptor ACE2 in different populations","volume":"6","author":"Cao","year":"2020","journal-title":"Cell Discov"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00029330-200801010-00006","article-title":"Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy","volume":"121","author":"Wang","year":"2008","journal-title":"Chin Med J"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2020.109920_b0160","first-page":"167","article-title":"ACE2, CALM3 and TNNI3K polymorphisms as potential disease modifiers in hypertrophic and dilated cardiomyopathies","volume":"438","author":"Kumar","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.mehy.2020.109920_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102434","article-title":"The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China","volume":"109","author":"Yang","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.mehy.2020.109920_b0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fmicb.2019.00050","article-title":"Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/v11010039","article-title":"Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV","volume":"11","author":"Jiang","year":"2019","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.mehy.2020.109920_b0185","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"6","key":"10.1016\/j.mehy.2020.109920_b0190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40071","article-title":"Review: cytokine storm syndrome: looking toward the precision medicine era","volume":"69","author":"Behrens","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.mehy.2020.109920_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"10223","key":"10.1016\/j.mehy.2020.109920_b0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mehy.2020.109920_b0210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"10.1016\/j.mehy.2020.109920_b0215","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1128\/JVI.06791-11","article-title":"Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge","volume":"86","author":"Clay","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.109920_b0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"Levi","year":"2017","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13613-019-0499-6","article-title":"Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study","volume":"9","author":"Schmitt","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"5","key":"10.1016\/j.mehy.2020.109920_b0230","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2020.109920_b0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12959-019-0205-9","article-title":"Hypoxia and HIF activation as a possible link between sepsis and thrombosis","volume":"17","author":"Evans","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.mehy.2020.109920_b0240","unstructured":"Smith T, Bushek J, Prosser T. COVID-19 drug therapy -potential options. Clinical Drug Information - Clinical Solutions. Elsevier. Accessed on May 6, 2020 at https:\/\/www.elsevier.com\/__data\/assets\/pdf_file\/0016\/1004173\/COVID-19-Drug-Therapy_4.30.2020.pdf."},{"issue":"4","key":"10.1016\/j.mehy.2020.109920_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine","volume":"55","author":"Sahraei","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.109920_b0250","unstructured":"Duan YJ, Liu Q, Zhao SQ, et al. The trial of chloroquine in the treatment of corona virus disease 2019 COVID-19 and its research progress in forensic toxicology. Fa Yi Xue Za Zhi 2020;36(2). 10.12116\/j.issn.1004-5619.2020.02.001."},{"key":"10.1016\/j.mehy.2020.109920_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antivir Res"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"20","key":"10.1016\/j.mehy.2020.109920_b0265","first-page":"30390","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"S0883\u20139441","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.mehy.2020.109920_b0270","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.mehy.2020.109920_b0275","first-page":"ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2020.109920_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.109920_b0285","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1223","article-title":"A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19","author":"Kim","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mehy.2020.109920_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell Mol Immunol"},{"issue":"01","key":"10.1016\/j.mehy.2020.109920_b0300","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1142\/S0192415X19500071","article-title":"Rhein, an anthraquinone drug, suppresses the NLRP3 inflammasome and macrophage activation in urate crystal-induced gouty inflammation","volume":"47","author":"Chang","year":"2019","journal-title":"Am J Chin Med"},{"key":"10.1016\/j.mehy.2020.109920_b0305","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2147\/DDDT.S133069","article-title":"Rhein attenuates inflammation through inhibition of NF-\u03baB and NALP3 inflammasome in vivo and in vitro","volume":"11","author":"Ge","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.mehy.2020.109920_b0310","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.intimp.2019.03.030","article-title":"Rhein protects against barrier disruption and inhibits inflammation in intestinal epithelial cells","volume":"71","author":"Zhuang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.mehy.2020.109920_b0315","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3389\/fphar.2019.01600","article-title":"Rhein suppresses lung inflammatory injury induced by human respiratory syncytial virus through inhibiting NLRP3 inflammasome activation via NF-\u03baB pathway in mice","volume":"10","author":"Shen","year":"2020","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2020.109920_b0320","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0945-053X(02)00028-8","article-title":"Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: molecular and cellular aspects","volume":"21","author":"Dozin","year":"2002","journal-title":"Matrix Biol"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0325","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.3892\/mmr.2015.3925","article-title":"Rhein inhibits lipopolysaccharide-induced intestinal injury during sepsis by blocking the toll-like receptor 4 nuclear factor-\u03baB pathway","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0330","first-page":"5","article-title":"Efficacy and safety of diacerein and diclofenac in knee osteoarthritis in Indian patients - a prospective randomized open label study","volume":"1","author":"Gupta","year":"2012","journal-title":"J Biomed"},{"key":"10.1016\/j.mehy.2020.109920_b0335","doi-asserted-by":"crossref","first-page":"11822","DOI":"10.1038\/srep11822","article-title":"Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-\u03baB activities","volume":"5","author":"Yu","year":"2015","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0340","first-page":"19","article-title":"Anti-inflammatory effects of rhein and crude extracts from Cassia alata L. HaCaT cells","volume":"12","author":"Wadkhien","year":"2015","journal-title":"Sci Eng Health Stud"},{"issue":"6","key":"10.1016\/j.mehy.2020.109920_b0345","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.intimp.2008.01.020","article-title":"Diacerhein downregulate proinflammatory cytokines expression and decrease the autoimmune diabetes frequency in nonobese diabetic (NOD) mice","volume":"8","author":"Malaguti","year":"2008","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.mehy.2020.109920_b0350","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00011-019-01239-7","article-title":"Chrysophanol, an anthraquinone from AST2017-01, possesses the anti-proliferative effect through increasing p53 protein levels in human mast cells","volume":"68","author":"Han","year":"2019","journal-title":"Inflamm Res"},{"issue":"5","key":"10.1016\/j.mehy.2020.109920_b0355","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000107690","article-title":"Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract","volume":"53","author":"Li","year":"2007","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191793","article-title":"Anti-influenza A virus activity of rhein through regulating oxidative stress, TLR4, Akt, MAPK, and NF-\u03baB signal pathways","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0365","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.antiviral.2006.04.014","article-title":"Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction","volume":"74","author":"Ho","year":"2007","journal-title":"Antivir Res"},{"issue":"33","key":"10.1016\/j.mehy.2020.109920_b0370","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.mehy.2020.109920_b0375","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijbiomac.2016.10.001","article-title":"Quinazoline derivatives as cathepsins B, H and L inhibitors and cell proliferating agents","volume":"94","author":"Raghav","year":"2017","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0380","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-5793(88)80028-0","article-title":"Amino acid sequences of the human kidney cathepsins H and L","volume":"228","author":"Ritonja","year":"1988","journal-title":"FEBS Lett"},{"issue":"461","key":"10.1016\/j.mehy.2020.109920_b0385","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BLO.0b013e3180533b5c","article-title":"Anthraquinone-2,6-disulfonic acid as a disease-modifying osteoarthritis drug","volume":"461","author":"Savarino","year":"2007","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"10.1016\/j.mehy.2020.109920_b0390","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/jth.14781","article-title":"Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia","volume":"18","author":"Lillicrap","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2020.109920_b0395","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China","author":"Shi","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.mehy.2020.109920_b0400","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2020.109920_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phymed.2018.06.029","article-title":"Rhein protects the myocardiac cells against hypoxia\/reoxygention-induced injury by suppressing GSK3\u03b2 activity","volume":"51","author":"Liu","year":"2018","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.mehy.2020.109920_b0410","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/np50069a014","article-title":"Potential inhibitors of platelet aggregation from plant sources, V. Anthraquinones from seeds of Cassia obtusifolia and related compounds","volume":"53","author":"Yun-Choi","year":"1990","journal-title":"J Nat Prod"},{"issue":"2","key":"10.1016\/j.mehy.2020.109920_b0415","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1254\/jphs.11123FP","article-title":"Chrysophanol-8-O-glucoside, an anthraquinone derivative in rhubarb, has antiplatelet and anticoagulant activities","volume":"118","author":"Seo","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.mehy.2020.109920_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2019.04.018","article-title":"Anthraquinones from Cassiae semen as thrombin inhibitors: in vitro and in silico studies","volume":"165","author":"Yu","year":"2019","journal-title":"Phytochemistry"},{"issue":"1","key":"10.1016\/j.mehy.2020.109920_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030005","article-title":"A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice","volume":"3","author":"Roberts","year":"2007","journal-title":"PLoS Pathog"},{"issue":"541","key":"10.1016\/j.mehy.2020.109920_b0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.mehy.2020.109920_b0435","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0006-2952(00)00411-1","article-title":"Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative","volume":"60","author":"Yuk","year":"2000","journal-title":"Biochem Pharmacol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720311828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720311828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:22:41Z","timestamp":1759692161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720311828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":87,"alternative-id":["S0306987720311828"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109920","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diacerein: A potential multi-target therapeutic drug for COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.109920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109920"}}